Please select the option that best describes you:
Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?
Will you await manuscript publication and formal regulatory approval prior to routinely instituting this treatment?
Answer from: Medical Oncologist at Academic Institution
The data presented at ESMO were paradigm-shifting. Within the constraints of insurance coverage, I will offer EVP to all patients with untreated metastatic urothelial cancer who are otherwise candidates for this therapy.
Sign in or Register to read more